Serum lipids and breast cancer risk: A meta-Analysis of prospective cohort studies

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Ni, Haibo ^a   Liu, Huixiang ^a   Gao, Rong ^a  

^a Suzhou Medical College of Soochow University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; BREAST CANCER; CANCER RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DISEASE ASSOCIATION; HUMAN; LIPID BLOOD LEVEL; POSTMENOPAUSE; PREMENOPAUSE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BREAST NEOPLASMS; FEMALE; META ANALYSIS; RISK;

BREAST NEOPLASMS; FEMALE; HUMANS; LIPIDS; RISK;

EID: 84953286690     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142669     Document Type: Article

References (55)

1. Araújo F, Gouvinhas C, Fontes F, La Vecchia C, Azevedo A, Lunet N. Trends in cardiovascular diseases and cancer mortality in 45 countries from five continents (1980-2010). Eur J Prev Cardiol. 2013; 21: 1004-1017. doi: 10.1177/2047487313497864
2. Smith DG. Epidemiology of dyslipidemia and economic burden on the healthcare system. The Am J Manag Care. 2007; 13 Suppl 3: S68-71.
3. Danilo C, Frank PG. Cholesterol and breast cancer development. Curr Opin Pharmacol. 2012; 12: 677-682. doi: 10.1016/j.coph.2012.07.009
4. Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol. 2007; 630: 148-165.
5. Hoyer AP, Engholm G. Serum lipids and breast cancer risk: A cohort study of 5, 207 Danish women. Cancer Causes Control. 1992; 3: 403-408.
6. Gaard M, Tretli S, Urdal P. Risk of breast cancer in relation to blood lipids: A prospective study of 31, 209 Norwegian women. Cancer Causes Control. 1994; 5: 501-509.
7. Furberg AS, Veierod MB, Wilsgaard T, Berstein L, Thune I. Serum high density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst. 2004; 96: 1152-1160.
8. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Archives of internal medicine. 2005; 165: 2264-2271.
9. Kucharska-Newton AM, Rosamond WD, Mink PJ, Alberg AJ, Shahar E, Folsom AR. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann Epidemiol. 2008; 18: 671-677. doi: 10. 1016/j.annepidem.2008.06.006
10. Kabat GC, Kim M, Chlebowski RT, Khandekar J, Ko MG, McTiernan A, et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2046-2053. doi: 10.1158/1055-9965.EPI-09-0235
11. Inoue M, Noda M, Kurahashi N, Iwasaki M, Sasazuki S, Iso H, et al. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev. 2009; 18: 240-247.
12. Iso H, Ikeda A, Inoue M, Sato S, Tsugane S, Group JS. Serum cholesterol levels in relation to the incidence of cancer: The JPHC study cohorts. Int J Cancer. 2009; 125: 2679-2686. doi: 10.1002/ijc.24668
13. Bjorge T, Lukanova A, Jonsson H, Tretli S, Ulmer H, Manjer J, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1737-1745. doi: 10.1158/1055-9965.EPI-10-0230
14. Fagherazzi G, Fabre A, Boutron-Ruault MC, Clavel-Chapelon F. Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort. Eur J Cancer Prev. 2010; 19: 120-125.
15. Kitahara CM, De Gonzalez AB, Freedman ND, Huxley R, Mok Y, Jee SH, et al. Total cholesterol and cancer risk in a large prospective study in Korea. Journal of Clinical Oncology. 2011; 29: 1592-1598. doi: 10.1200/JCO.2010.31.5200
16. Bosco JLF, Palmer JR, Boggs DA, Hatch EE, Rosenberg L. Cardiometabolic factors and breast cancer risk in U.S. black women. Breast Cancer Res Treat. 2012; 134: 1247-1256. doi: 10.1007/s10549-012-2131-4
17. Melvin JC, Seth D, Holmberg L, Garmo H, Hammar N, Jungner I, et al. Lipid profiles and risk of breast and ovarian cancer in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1381-1384. doi: 10.1158/1055-9965.EPI-12-0188
18. Strohmaier S, Edlinger M, Manjer J, Stocks T, Bjorge T, Borena W, et al. Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PLoS One. 2013; 8: e54242. doi: 10.1371/journal.pone.0054242
19. His M, Zelek L, Deschasaux M, Pouchieu C, Kesse-Guyot E, Hercberg S, et al. Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. Eur J Epidemiol. 2014; 29: 119-132. doi: 10.1007/s10654-014-9884-5
20. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Rafaniello C, et al. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-Analysis. Menopause. 2013; 20: 1301-1309.
21. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-Analyses. Eur J Epidemiol. 2010; 25: 603-605. doi: 10.1007/s10654-010-9491-z
22. Hamling J, Lee P, Weitkunat R, Amböhl M. Facilitating meta-Analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med. 2008; 27: 954-970.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-Analyses. BMJ. 2003; 327: 557-560.
24. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997; 127: 820-826.
25. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-Analysis. Am J Epidemiol. 1992; 135: 1301-1309.
26. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata Journal. 2006; 6: 40-57.
27. Manjer J, Kaaks R, Riboli E, Berglund G. Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: A prospective study within the Malmo Preventive Project. Eur J Cancer Prev. 2001; 10: 33-42.
28. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50: 1088-1101.
29. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-Analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634.
30. Mainous IAG, Wells BJ, Koopman RJ, Everett CJ, Gill JM. Iron, lipids, and risk of cancer in the Framingham offspring cohort. Am J Epidemiol. 2005; 161: 1115-1122.
31. Reeves KW, McLaughlin V, Fredman L, Ensrud K, Cauley JA. Components of metabolic syndrome and risk of breast cancer by prognostic features in the study of osteoporotic fractures cohort. Cancer Causes Control. 2012; 23: 1241-1251. doi: 10.1007/s10552-012-0002-2
32. Osaki Y, Taniguchi SI, Tahara A, Okamoto M, Kishimoto T. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol. 2012; 36: 141-147. doi: 10.1016/j.canep.2011.03. 007
33. Moorman PG, Hulka BS, Hiatt RA, Krieger N, Newman B, Vogelman JH, et al. Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. Cancer Epidemiol Biomarkers Prev. 1998; 7: 483-488.
34. Agnoli C, Berrino F, Abagnato CA, Muti P, Panico S, Crosignani P, et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: A nested case-control study. Nutr Metab Cardiovasc Dis. 2010; 20: 41-48. doi: 10.1016/j.numecd.2009.02.006
35. Capasso I, Esposito E, Pentimalli F, Crispo A, Montella M, Grimaldi M, et al. Metabolic syndrome affects breast-cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol Ther. 2010; 10: 1240-1243.
36. Vatten LJ, Foss OP. Total serum cholesterol and triglycerides and risk of breast cancer: A prospective study of 24, 329 Norwegian women. Cancer Res. 1990; 50: 2341-2346.
37. Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L. Breast cancer incidence in ex-smokers in relation to body mass index, weight gain and blood lipid levels. Eur J Cancer Prev. 2001; 10: 281-287.
38. Ha M, Sung J, Song YM. Serum total cholesterol and the risk of breast cancer in postmenopausal Korean women. Cancer Causes Control. 2009; 20: 1055-1060. doi: 10.1007/s10552-009-9301-7
39. Borena W, Stocks T, Jonsson H, Strohmaier S, Nagel G, Bjorge T, et al. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control. 2011; 22: 291-299. doi: 10.1007/s10552-010-9697-0
40. Hiatt RA, Friedman GD, Bawol RD, Ury HK. Breast cancer and serum cholesterol. J Natl Cancer Inst. 1982; 68: 885-889.
41. Tornberg SA, Holm LE, Carstensen JM. Breast cancer risk in relation to serum cholesterol, serum betalipoprotein, height, weight, and blood pressure. Acta Oncol. 1988; 27: 31-37.
42. Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L. Risk factors for malignant diseases: A cohort study on a population of 22, 946 Icelanders. Cancer Epidemiol Biomarkers Prev. 1997; 6: 863-873.
43. Nelson ER, Chang CY, McDonnell DP. Cholesterol and breast cancer pathophysiology. Trends Endocrinol Metab. 2014; 25: 649-655. doi: 10.1016/j.tem.2014.10.001
44. Sarrel PM. Cardiovascular aspects of androgens in women. Semin Reprod Endocrinol. 1997; 16: 121-128.
45. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev. 1992; 15: 48-65.
46. Kelley GA, Kelley KS, Roberts S, Haskell W. Comparison of aerobic exercise, diet or both on lipids and lipoproteins in adults: A meta-Analysis of randomized controlled trials. Clin Nutr. 2012; 31: 156-67. doi: 10.1016/j.clnu.2011.11.011
47. Rossi RE, Pericleous M, Mandair D, Whyand T, Caplin ME. The role of dietary factors in prevention and progression of breast cancer. Anticancer Res. 2014; 34: 6861-75.
48. Ray G, Husain SA. Role of lipids, lipoproteins and vitamins in women with breast cancer. Clin Biochem. 2001; 34: 71-76.
49. Boyd N, McGuire V. The possible role of lipid peroxidation in breast cancer risk. Free Radic Biol Med. 1991; 10: 185-190.
50. Esteve E, Ricart W, Fernandez-Real JM. Dyslipidemia and inflammation: An evolutionary conserved mechanism. Clin Nutr. 2005; 24: 16-31.
51. Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, Köppel H, et al. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2005; 90: 113-115.
52. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005; 14: 699-704.
53. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-Analysis of population-based prospective studies. J Cardiovasc Risk. 1996; 3: 213-219.
54. Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: A meta-Analysis of observational studies. Breast Cancer Res Treat. 2012; 135: 261-269. doi: 10.1007/s10549-012-2154-x
55. Abdelsalam KE, Hassan IK, Sadig IA. The role of developing breast cancer in alteration of serum lipid profile. J Res Med Sci. 2012; 17: 562-565.